ELF5 in epithelial ovarian carcinoma tissues and biological behavior in ovarian carcinoma cells

Abstract

The expression of E74-like factor 5 (ELF5) in epithelial ovarian carcinoma tissues and its effects on biological behavior in ovarian carcinoma cells were assessed in search for a new approach for gene treatment of epithelial ovarian carcinoma. RT-PCR technology was applied to detect the expression of ELF5 mRNA in epithelial ovarian carcinoma (n=49), borderline ovarian epithelial tumor (n=19), benign ovarian epithelial tumor (n=31) and normal ovarian tissues (n=40). Then, we transfected recombinant plasmid pcDNA3.1-ELF5+EGFP into human ovarian carcinoma SKOV3 cells (recombinant plasmid group) in vitro and screened out stably transfected cells to conduct multiplication culture. Western blot analysis was performed to detect the expression of ELF5 protein in the different groups. Flow cytometry was employed to detect cell apoptosis and cycles. ELF5 mRNA in epithelial ovarian carcinoma and borderline ovarian epithelial tumor tissues were significantly lower (P<0.05) than those in benign ovarian epithelial tumor and normal ovarian tissues. ELF5 protein expression in the cells of recombinant plasmid group was significantly higher compared with empty plasmid and blank control groups. The capacity of cell reproductive recombinant plasmid group at each time point decreased (P<0.05). Flow cytometry detection showed that 67.03% of cells in recombinant plasmid group was blocked in G0/G1 phase (P<0.05), compared with empty plasmid group (37.17%) and blank control group (38.24%). Apoptotic rate of recombinant plasmid group was significantly lower (31.4±1.9%; P<0.05), compared with that of empty plasmid group (9.1±2.2%) and blank control group (8.7±1.5%), and the differences were statistically significant. In conclusion, ELF5 interfered with cell cycle of human ovarian carcinoma SKOV3 cells and promoted apoptosis of human ovarian carcinoma SKOV3 cells inhibiting their growth and invasive capacity; and thus providing a new approach to gene treatment of ovarian carcinoma.

ELF3, ELF5, EHF and SPDEF Transcription Factors in Tissue Homeostasis and Cancer

“…The majority of evidence generated to date indicates ELF5 plays a tumour suppressive role in prostate [ 59 , 60 ], bladder [ 61 ], ovarian [ 62 ] and renal cancer [ 63 ]. In prostate cancer, loss of ELF5 protein expression correlates with loss of expression of the epithelial marker E-Cadherin and increased expression of the mesenchymal marker N-Cadherin [ 59 ].…”

“…Finally, ELF5 mRNA expression in ovarian cancer [ 62 ] and ELF5 mRNA and protein in renal cell carcinoma [ 63 ] is reduced compared to corresponding normal tissue, and re-expression of ELF5 in cell line models of these cancers inhibits cell proliferation and survival [ 62 , 63 ].…”

Expression and clinical significance of WWOX, Elf5, Snail1 and EMT related factors in epithelial ovarian cancer

“…Lee and Ormandy (10) showed that the E3 domain of Elf5 is rich in proline and has protein binding function, while the WW1 domain in the WWOX protein binds to a proline-rich domain, and the WWOX protein interacts with the transcription factor Elf5 through this property. The transcription factor Elf5 is not only involved in cell development, differentiation and apoptosis, but also regulates cell proliferation and tumorigenesis (11). Yan et al (12) showed that WWOX mRNa expression in ovarian cancer tissues was lower than that in normal ovarian tissue.…”

“…Yan et al (12) showed that WWOX mRNa expression in ovarian cancer tissues was lower than that in normal ovarian tissue. Yan et al (11) showed that the expression of Elf5 mRNa in ovarian cancer tissues was lower than that in normal ovarian tissues. In this study, the expression of WWOX and Elf5 in 300 ovarian cancer tissues and adjacent normal tissues were detected by immunohistochemical method.…”

Expression of ELF5 in endometrial carcinoma tissues and its clinical significance

“…It might inhibit the invasion and metastasis of ovarian cancer cells by regulation of matrix metalloproteinase-2 (MMP-2) and MMP-9. In this way, it accelerates cell cycle and apoptosis by increasing the expressions of P21 and caspase-3 in the human ovarian cancer tissues ( 12 – 14 ). However, in endometrial carcinoma, the effects of ELF5 have not been fully revealed.…”